Abstract

BackgroundAllergic rhinitis is a symptomatic allergic disease of the nose that affects 10 to 20% of the global population. Chinese otolaryngologists use one acupuncture needle to stimulate the sphenopalatine ganglion because of its potential advantages for treating moderate-severe persistent allergic rhinitis compared with traditional Chinese acupuncture (verum acupuncture); however, little evidence is available to support the wide clinical use thus far. Therefore, we propose a protocol for a parallel, multicenter, assessor-blinded, randomized controlled trial to evaluate sphenopalatine ganglion stimulation with one acupuncture needle compared to verum acupuncture for treatment of moderate-severe persistent allergic rhinitis.MethodsIn the trial, 96 patients previously diagnosed with moderate-severe persistent allergic rhinitis and meeting all inclusion criteria will be allocated to one of two equal therapeutic groups by using a computer-generated randomization list. The interventional group will receive sphenopalatine ganglion stimulation with one acupuncture needle for 4 weeks (once or twice weekly, total four to eight sessions); attending physicians will decide whether the second session is required in a week by examining signs and symptoms. The control group will receive individualized verum acupuncture for 4 weeks (twice weekly, total eight sessions). Follow-up evaluations will be performed 1 month later. The primary outcome measure is the change in the total nasal symptom score from the baseline to week 4. The secondary outcome measures include onset time and duration of effectiveness in every session, change in number of days with moderate-severe persistent allergic rhinitis from the baseline to week 8, change in total immunoglobulin E level and eosinophil count in venous blood from the baseline to week 4, change in Rhinoconjunctivitis Quality of Life Questionnaire score from the baseline to week 4, and clinical waiting time.DiscussionThe trial should provide evidence for the benefits of sphenopalatine ganglion stimulation with one acupuncture needle for treating moderate-severe persistent allergic rhinitis, including better change in total nasal symptom score, faster onset time, longer duration of effectiveness, and shorter treatment time.Trial registrationCurrent Controlled Trials: ISRCTN21980724 (registered on 27 March 2014).Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-015-0707-0) contains supplementary material, which is available to authorized users.

Highlights

  • Methods96 patients previously diagnosed with moderate-severe persistent allergic rhinitis and meeting all inclusion criteria will be allocated to one of two equal therapeutic groups by using a computer-generated randomization list

  • Allergic rhinitis is a symptomatic allergic disease of the nose that affects 10 to 20% of the global population

  • A large case study suggested that sphenopalatine ganglion stimulation with one acupuncture needle, a technique developed by a Chinese otolaryngologist and applied in more than 130,000 Chinese patients [9], offers potential advantages with regard to nasal symptoms, onset time, duration of effectiveness, and quality of life

Read more

Summary

Methods

Ethics The study design and methodology adhere to the principles of the Declaration of Helsinki and have been approved by the Xiyuan Hospital Ethics Committee (December 31, 2013; approval number 2013XL062-2). Blinded telephone interviewers will contact the participants regarding the days of moderate to severe allergic rhinitis during the 4 weeks after the treatment period to evaluate the long-term effect of acupuncture in the 8th week after randomization. Sanyinjiao (SP36) Perpendicular to the skin between the basline (week 0) and week 4, onset time and duration of effectiveness in every session, change in the number of symptomatic days from the baseline to the end of the follow-up (week 8), change in total IgE level and eosinophil count in venous blood from the baseline to week 4, change in RQLQ score from the baseline to week 4, and clinical waiting time (Table 2). Participants will be asked to record symptoms from the baseline to week 4 in a rhinitis diary They will be required to note the use of relief medication (cetirizine dihydrochloride film-coated tablets) prescribed by the physicians for acute symptoms of allergic rhinitis, including dosage, ingestion time, relief time, and side effects. All analyses will be performed in SPSS version 13.0 (SPSS, Chicago, IL)

Discussion
Background
Findings
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.